International Cancer Imaging Society Development Site


Our Journal - Cancer Imaging

Cancer Imaging is the official journal of ICIS, an open access, peer-reviewed journal published by BioMed Central. Original articles, as well as reviews and editorials written by international imaging experts with a subspecialty focus on oncology, are published regularly online;  sign up for alerts to keep up-to-date with the latest articles.

Cancer Imaging Impact factor is 3.153.

2018 Abstract Book

The journal encompasses CT, MRI, ultrasound, single photon and positron emission tomography, including multimodality imaging in all kinds of malignant tumours, plus new developments, techniques and innovations.

All articles published in Cancer Imaging are included in PubMed, the most widely used biomedical bibliographic database service, as well as Embase, EmCare, Google Scholar, MEDLINE, Science Citation Index and Scopus. The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature.

ICIS Members receive 20% discount on article-processing fees.

Submit your next manuscript to Cancer Imaging and take full advantage of the following:


Members Area


Subscribe to our mailing list

If you want to be kept up to date on what's happening with ICIS or to Register your Interest in one of our courses, click on the Subscribe button below.

* indicates required

Cancer / Oncology News From Medical News Today

How to stimulate appetite

Published: Fri, 23 Aug 2019 10:00:00 PDT

Appetite stimulants include various medications and supplements, as well as lifestyle strategies. Learn more about how to stimulate appetite here.

Is 5G technology bad for our health?

Published: Fri, 23 Aug 2019 08:00:00 PDT

In this Spotlight, we look at the effects of electromagnetic fields on our bodies and explore why some think 5G tech may not be safe.

Antibiotics and bowel cancer: Study finds link

Published: Wed, 21 Aug 2019 00:00:00 PDT

A study looking at antibiotics and bowel cancer concludes that the drugs might increase the risk of colon cancer, but lower the risk of rectal cancer.

Cancer more common in females with severe sleep apnea

Published: Tue, 20 Aug 2019 09:00:00 PDT

A new study of 20,000 adults with sleep apnea suggests that the risk of cancer could be 2–3 times higher among females with a severe form of the condition.

What to know about HER2-negative breast cancer

Published: Mon, 19 Aug 2019 17:00:00 PDT

There are two main types of HER2-negative breast cancer: hormone receptor-positive and triple-negative. Many treatments exist, and prognosis varies. Learn more here.

The power of electromagnetic energy on breast cancer cells

Published: Sat, 17 Aug 2019 03:00:00 PDT

Electromagnetic energy could be used to halt the movement of breast cancer cells, reducing metastatic cases. New research explains how.

Simple dietary changes may reduce cancer risk, increase lifespan

Published: Fri, 16 Aug 2019 03:00:00 PDT

The health benefits of fruit and vegetables are partly due to flavonoids. A new study concludes that consuming more flavonoids each day may extend life.

Gleevec (imatinib)

Published: Thu, 15 Aug 2019 00:00:00 PDT

Gleevec (imatinib) is a brand-name prescription medication. It’s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It’s also used to treat certain types of skin cancer and gastrointestinal cancer. Learn about side effects and more.

Xospata (gilteritinib)

Published: Thu, 15 Aug 2019 00:00:00 PDT

Xospata (gilteritinib) is a brand-name prescription medication. It’s used to treat a specific form of acute myeloid leukemia (AML) in adults whose cancer relapsed (returned) or didn’t respond to other treatments. Xospata comes as an oral tablet that you take daily. Learn about side effects, dosage, cost, and more.

Can itchy armpits be a sign of cancer?

Published: Wed, 14 Aug 2019 13:00:00 PDT

Itchy armpits may occasionally be due to cancer, although there are many more likely causes. Infections and underlying skin conditions are some other reasons. Learn more here.

Corporate Sponsors

Guerbet
Siemens

ICIS would like to acknowledge the generous support of our Corporate Sponsors.

News

25 April 2019

ICIS 2019 - Sponsored Delegate Opportunity

ICIS 2019 - Sponsored Delegate Opportunity


» Read more » Other news items